Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Ovarian Neoplasms 18Uterine Cervical Neoplasms 6Recurrence 2Neoplasms 2Gestational Trophoblastic Disease 2Carcinoma, Ovarian Epithelial 2Uterine Neoplasms 1Triple Negative Breast Neoplasms 1Stomach Neoplasms 1Sarcoma 1Ovarian Cancer Recurrent 1Fallopian Tube Neoplasms 1Esophageal Neoplasms 1Endometrial Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1Angiogenesis Inhibitors,Ovarian Neoplasms 1

Interventions

Paclitaxel 4liposomal doxorubicin 3Carboplatin 3pembrolizumab 2Bevacizumab 21-dodecylpyridoxal 2poly(I).poly(c12,U) 1mirabegron 1disitamab vedotin 1apatinib 1anlotinib 1Tocotrienols 1Platinum Compounds 1Lenalidomide 1Interferon alpha-2 1Hyperthermic Intraperitoneal Chemotherapy 1Gemcitabine 1EP-100 membrane-disrupting peptide 1Cisplatin 1AC 7700 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Ovarian Cancer Recurrent × apatinib × Gynecologic × Clear all
NCT06102707 2023-10-26

The Efficacy and Safety of Fluzopril Combined With Apatinib in Maintenance Treatment of Platinum Resistant Recurrent Ovarian Cancer Patients

Qilu Hospital of Shandong University

Phase NA Not yet recruiting
50 enrolled
Gynecologic

Ovarian Cancer Recurrent

Data powered by HemOnc (CC BY 4.0) Colophon âš¡